153 related articles for article (PubMed ID: 11789562)
1. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer.
Imamoto T; Suzuki H; Akakura K; Komiya A; Nakamachi H; Ichikawa T; Igarashi T; Ito H
Endocr J; 2001 Oct; 48(5):573-8. PubMed ID: 11789562
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
4. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
[TBL] [Abstract][Full Text] [Related]
5. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Furuya Y; Nozaki T; Nagakawa O; Fuse H
Endocr J; 2002 Feb; 49(1):85-90. PubMed ID: 12008754
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
8. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.
Imamoto T; Suzuki H; Fukasawa S; Shimbo M; Inahara M; Komiya A; Ueda T; Shiraishi T; Ichikawa T
Eur Urol; 2005 Mar; 47(3):308-12. PubMed ID: 15716191
[TBL] [Abstract][Full Text] [Related]
10. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.
Kamada S; Sakamoto S; Ando K; Muroi A; Fuse M; Kawamura K; Imamoto T; Suzuki H; Nagata M; Nihei N; Akakura K; Ichikawa T
J Urol; 2015 Nov; 194(5):1264-70. PubMed ID: 25861958
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
12. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.
Matzkin H; Soloway MS; Schellhammer PF; Chodak G; Smith JA; Caplan R; Kennealey GT
Cancer; 1993 Aug; 72(4):1286-90. PubMed ID: 8339217
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
16. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.
Zagars GK; Pollack A; von Eschenbach AC
Urology; 1997 Mar; 49(3):327-34. PubMed ID: 9123693
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
[TBL] [Abstract][Full Text] [Related]
19. Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer?
Patel A
J Urol; 2021 Mar; 205(3):806-811. PubMed ID: 33035140
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
